Cost Effectiveness of Rivaroxaban (Xarelto®) for the prevention of stroke in atrial fibrillation.
|17/08/2011||31/08/2011||Full Pharmacoeconomic Evaluation Recommended|
|11/11/2011||02/4/2012||Reimbursement not Recommended|
The NCPE do not believe that rivaroxaban is cost effective for this indication at the submitted price.
Following the NCPE pharmacoeconomic assessment (2/4/2012) the manufacturer reduced the price of rivaroxaban (23/5/2012). At this revised price we now consider rivaroxaban cost effective for this indication. A positive recommendation was made on the 19/6/2012.